295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.
Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.
Antimicrobial resistance in the Netherlands is remaining reasonably stable Antimicrobial resistance is increasing on a global level. It is difficult to treat infections caused by resistant bacteria.
Updated immunisation recommendation for measles: early vaccination before travel A number of European countries are currently seeing outbreaks of measles. Before the start of the summer season, RIVM has therefore updated its immunisation recommendation for measles.
Biosafety and Biosecurity on the Global Health Security Agenda Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.